drug hunter @drughunter_com
the science of drug discovery, distilled for industry innovators. discover more by subscribing at: https://t.co/FnfsOmSXe4 drughunter.com Joined March 2021-
Tweets1K
-
Followers11K
-
Following26
-
Likes237
A single-dose cure has arrived for HAT (human African trypanosomiasis). Acoziborole is a benzoxaborole, a reversibly-covalent binder of CPSF3 in Trypanosoma parasites that leaves human CPSF3 untouched. The compound cured patients in both early- and late-stage disease, differentiating itself from the other completely oral HAT regimen, fexinidazole, which is ineffective in severe stage 2 infections. Read more on Drug Hunter: drughunters.com/439VwNt
Milsaperidone (Bysanti®) was FDA approved in February 2026 for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. With a bridging package, milsaperidone reached FDA approval roughly five years after entering the clinic. Read it on Drug Hunter: drughunters.com/4ejPGz6
Ropsacitinib (PF-06826647) is a TYK2 inhibitor that reached Ph. 2 development in plaque psoriasis and hidradenitis suppurativa. Despite encouraging psoriasis data, ropsacitinib does not appear to be in active development today, while Priovant’s dual JAK1/TYK2 inhibitor brepocitinib has become the clearer priority. Read more on Drug Hunter: drughunters.com/4dJC8gc
June is Alzheimer’s & Brain Awareness Month – and the urgency around neurodegenerative diseases drug discovery has never been clearer. Two mechanistically distinct approaches are generating serious scientific momentum, and our team at Drug Hunter published in-depth analyses on both: -TREM2 Agonists in Neurodegeneration: TREM2 signaling sits at the intersection of microglial activation, synaptic pruning, and amyloid clearance. Our analysis covers the therapeutic potential, translational data, key pharmacological challenges, and the emerging competitive landscape surrounding TREM2-targeted approaches across Alzheimer’s disease and related neurodegenerative disorders. -RNA Splice Modulators in CNS: Small molecule splice modulators are moving beyond their rare disease origins. The development of orally bioavailable RNA-targeting small molecules offer an advantage over existing RNA-targeting modalities such as siRNA, antisense oligonucleotides, biologics, and gene therapy. Our analysis discusses how RNA splice modulation strategies are being applied to complex CNS indications. Both analyses are available with complimentary access following a short platform demo. Reach out or click the link below to schedule. drughunters.com/4o0yAJO #AlzheimersAwarenessMonth #Neurodegeneration #CNS #DrugDiscovery #Biotech #AlzheimersDisease
The Drug Hunter team reviews thousands of IP disclosures each month to highlight the most impactful drug discovery patents. For April 2026, we analyzed and curated a searchable dataset of the most noteworthy disclosures, offering key data, molecular insights, and therapeutic relevance. Highlighted disclosures: -1cBio: ENPP1 inhibitors for hypophosphatasia -Arrakis Therapeutics: heterobinfunctional degraders of RNA targeting CNOT9 -Kaken Pharmaceutical: Small molecule STAT6 inhibitors -Atrogi: biased β2-adrenergic receptor agonists for obesity and metabolic disease -Para: VPS4A inhibitors targeting an untapped synthetic lethality relationship Read the full article on Drug Hunter: drughunters.com/4dQLgyx
A method that enables rapid access to glutarimides has been reported in a collaboration between the Baran Lab and BMS. Glutarimides are a key motif in the TPD (targeted protein degradation) field, and an array of scaffolds beyond those based on substituted thalidomides have entered clinical trials. However, only limited reports of glutarimides bearing α-sp3 hybridized substituents have emerged. In this Chemistry Brief, we highlight a useful extension of the nickel-catalyzed cross-coupling of hydrazides pioneered by the Baran lab and its application to scaffolds relevant to heterobifunctional and molecular glue degraders. Read it on Drug Hunter: drughunters.com/4faHOB5
Amino acids are the fundamental building blocks of proteins. Their primary sequence and the chemical properties of their side chains govern protein folding, enzyme catalysis, and molecular recognition. Explore our amino acids cheat sheet, which highlights the structures and key properties of the 21 amino acids found in the human proteome as well as their relevance in protein structure. We hope this cheat sheet serves as both a valuable resource and inspiration for drug hunters at all stages of their careers. Explore the cheat sheet on Drug Hunter: drughunters.com/49rVR1u
Paclitaxel (Taxol®) is a natural product drug first FDA approved in 1992 for ovarian cancer that later became a backbone therapy across multiple cancers. Although the program was threatened by low isolation yields and the ecological burden of harvesting Pacific yew bark, a semi-synthetic route from the more readily available natural product precursor 10-deacetylbaccatin III enabled large-scale production and helped bring paclitaxel to patients. Read more on Drug Hunter: drughunters.com/4dXLqEq
Discovery of Bexobrutideg, an Oral Targeted Degrader of BTK for the Treatment of B-cell Malignancies Thursday, July 2nd, 2026 8 AM PT | 11 AM ET | 5 PM CET BTK inhibitors targeting the orthosteric site of the protein are widely used for the treatment of B-cell malignancies. Despite significant progress, the emergence of BTK inhibitor resistant mutations is a persistent therapeutic challenge. In addition, BTK promotes BCR signaling through non-enzymatic scaffolding functions. These challenges highlight the need for therapies with an alternative mechanism of action. Bexobrutideg is an orally administered heterobifunctional small molecule degrader that acts to selectively eliminate both wild-type and mutant BTK from cells via cereblon-mediated ubiquitination and proteasomal degradation. In this Flash Talk, Barbara Czako, Executive Director of Medicinal Chemistry at Nurix Therapeutics will share the discovery story, preclinical characterization and Phase 1a/b safety and efficacy data for bexobrutideg. Register now to learn more about the discovery and preclinical and clinical findings surrounding this BTK degrader: drughunters.com/4fMZ0N6
Mitochondrial uncouplers increase energy expenditure by allowing protons to cross the inner mitochondrial membrane independently of ATP synthesis. By disconnecting mitochondrial metabolism from energy storage, these compounds increase fatty acid utilization and can reduce oxidative stress, creating therapeutic opportunities in obesity, metabolic disease, and inflammatory disorders. Unlike conventional weight-loss therapies, mitochondrial uncouplers do not directly suppress appetite and may better preserve lean mass. However, clinical development has historically been limited by narrow therapeutic windows and hyperthermia-associated toxicity. Recent advances in tissue-targeted prodrugs, controlled-release formulations, and next-generation protonophore scaffolds have renewed interest in the field. In parallel, low-dose mitochondrial uncoupling has shown promising effects in preclinical models of neurodegenerative disease, suggesting potential applications beyond metabolic disorders. After decades defined by on-mechanism toxicity, a new generation of mitochondrial uncouplers is now emerging with the potential to reshape how mitochondrial metabolism is therapeutically targeted. Read more on Drug Hunter: drughunters.com/4ebXKkz
Molecules of the Month – April 2026 Find out what molecules made our April 2026 Molecules of the Month list, and check out recent articles for each. Full article: drughunters.com/4dxKJ5z
In this Flash Talk, Ciaran Seath discussed the development and application of photoproximity labeling technologies for studying protein interactions in drug discovery. Ciaran presented two applications of this technology. µMap was used to investigate treatment-resistant HER2+ breast cancer cell lines and identified galectin-1 as a resistance-associated interactor whose inhibition restored sensitivity to HER2 immunotherapy. Ciaran also described how µMAP can be leveraged to identify context dependencies with challenging to drug targets. In MYC-driven prostate cancer a µMap approach identified the kinase SLK as a cancer-specific regulator of MYC stability. Although ubiquitously expressed, SLK accumulates in the nucleus specifically in high-risk AR-negative PC3 cells, where it physically interacts with and stabilizes MYC, revealing a previously unrecognized therapeutic vulnerability that would likely remain undetected using conventional omics approaches. If you would like to learn more about photoproximity labeling technologies and their applications in drug discovery, we encourage you to explore the full seminar and the associated preprint studies: drughunters.com/42RgwbF
On May 1, 2026, Arvinas and Pfizer’s vepdegestrant (Veppanu®) crossed the FDA finish line, marking a major milestone for targeted protein degradation. Vepdegestrant’s approval is an inflection point for the field—not just for PROTACs, but for next-generation degraders and other proximity-inducing modalities. Read more on Drug Hunter: drughunters.com/4e1ctzE
Next-Gen Utrophin Modulators for DMD: Learning from Clinical Setbacks Thursday, June 25th, 2026 8 AM PT | 11 AM ET | 5 PM CET Duchenne muscular dystrophy is a severe X-linked muscle-wasting disorder caused by mutations in the dystrophin gene, for which no curative treatment currently exists. In this Flash Talk, @Angela Russell, Professor of Medicinal Chemistry in the Departments of Chemistry and Pharmacology at the @University of Oxford, will present the discovery and clinical development of ezutromid, a first-in-class small-molecule utrophin modulator identified through phenotypic screening. She will discuss the early clinical data supporting the program and the findings that ultimately led to its discontinuation. Angela will also highlight mechanistic studies identifying AhR (aryl hydrocarbon receptor) as the molecular target of ezutromid and will highlight next-generation AhR antagonists with improved properties and efficacy as well as screening strategies leading to the identification of utrophin modulators with a distinct mechanism of action. Sign up now to learn more about utrophin modulators acting through AhR antagonism for the treatment of DMD and novel MoAs for utrophin modulation: drughunters.com/49jgnRT
TNG961: An HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers Presented by Hilary Nicholson of Tango Therapeutics at the AACR Annual Meeting 2026 New Drugs on the Horizon session, TNG961 is a potential first-in-class CRBN-mediated molecular glue degrader of HBS1L for FOCAD-deleted cancers, a subset of chr9p21-deleted tumors. FOCAD loss impairs SKI complex–mediated mRNA quality control, creating dependence on the HBS1L/PELO ribosome-rescue pathway. By selectively degrading HBS1L while sparing the closely related CRBN neosubstrate GSPT1, TNG961 disrupts this compensatory pathway and triggers translational stress in FOCAD-negative cells. Preclinically, TNG961 shows ~100-fold selectivity for FOCAD-deleted vs. WT cells and induces tumor regressions in pancreatic and NSCLC xenograft models, including tumors progressing on PRMT5 inhibitor treatment. Read more: drughunters.com/3PDrONp
DACs (degrader–antibody conjugates) combine catalytic protein degraders with mAb-mediated delivery to specific cell populations. This modality has the potential to improve tolerability and expand the therapeutic window relative to both cytotoxic ADCs and unconjugated degraders. However, the physicochemical properties of some degrader payloads—particularly their size and lipophilicity—together with the need for relatively high drug-to-antibody ratios, create significant developability challenges, including a high risk of aggregation. In addition, the multistep biological cascade required for DAC activity can lead to disconnects between the potency of free versus conjugated degraders, necessitating careful, multiparameter optimization. Despite these hurdles, several DACs have shown encouraging antigen-dependent activity, and recent disclosures of SMARCA2/4-targeting DACs suggest the potential for therapies with improved tolerability margins. Read the full review: drughunters.com/4eZY7AH
ASTX295: Designing a Short-Half-Life MDM2 Antagonist to Widen the Therapeutic Window ASTX295 is an MDM2 antagonist designed with a short half-life to deliver pulsatile p53 activation while potentially avoiding the prolonged exposure that has historically contributed to hematologic toxicity in this class of drugs. Early clinical data suggest that strategy may be working, with minimal hematologic toxicity reported in Ph. 1. After completion of the study, ASTX295 was in-licensed by Mosaic Therapeutics in 2025, and a Ph. 1b/2a study in combination with olaparib is now being prepared for biomarker-selected solid tumors. We highlight the discovery and characterization of ASTX295 presented at ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025. drughunters.com/3PiqeRc
Novartis Targets Cyclin E–Driven CDK4/6 Resistance with CDK2 Inhibitor NVP-ECI830 The structure of NVP-ECI830, Novartis’ oral CDK2-selective inhibitor, was revealed at the AACR 2026 New Drugs on the Horizon session. NVP-ECI830 displays high selectivity over other CDKs, single-agent efficacy in CCNE1-amplified tumor models, and enhanced activity with CDK4/6 inhibition in vivo. Interest in CDK2 has grown as preclinical studies have implicated cyclin E–CDK2 signaling as a bypass mechanism in cancers that develop resistance to standard-of-care CDK4/6 inhibitors. CDK2 may also represent a therapeutic vulnerability in tumors that overexpress cyclin E1. Several small-molecule CDK2 inhibitors have already entered the clinic, and CDK2 has also attracted attention in the targeted protein degradation field. However, no CDK2-selective modulator has yet received FDA approval. Read more on Drug Hunter: drughunters.com/4du5iyw
TRI-611: TRI-611: Targeting Resistant CNS Metastases with an ALK Molecular Glue Degrader TRI-611 represents a differentiated approach to treatment of ALK-positive NSCLC not otherwise accessible by orthosteric kinase inhibition. The CNS-penetrant, CRBN-mediated molecular glue degrader recruits a novel, non-G-loop degron distal to the orthosteric ALK site, which may help address inhibitor-driven acquired ALK mutations while preserving activity in a setting where brain metastases and limited post-TKI options remain major challenges. The FDA Fast Track-designated program is currently in Ph. 1/2 evaluation and was disclosed by Vito Palombella of TRIANA Biomedicines at the 2026 AACR New Drugs on the Horizon session. drughunters.com/4tMXrSO
Drug Hunter CEO, Dennis Hu, will host the Opening Plenary Keynote Panel at Discovery on Target 2026 in Boston. Tackling Difficult Drug Targets: A Modality-Agnostic & Technology-Nimble Approach Tuesday, September 29 | 4:50–6:05 PM Erin Davis, PhD — Vice President, Research Business Insights & Technology, Bristol Myers Squibb Ryan Potts, PhD — VP and Head, Induced Proximity Platform, Amgen John Tallarico, PhD — Global Head, Discovery Sciences, Novartis Biomedical Research Klaus Urbahns, PhD — Head, Therapeutic Modalities, Biogen Andrea Weston, PhD — Head of Discovery Biology and Pharmacology, Pfizer David Wilson, PhD — Vice President & Global Head, Oncology Chemistry & DMPK, AstraZeneca Six leaders from across the industry in one conversation about the strategy and science behind the most challenging targets. If you’re attending #BostonDOT, this is one to catch. Pre-register here: drughunters.com/4wCtS93
Keith Hornberger @KRHornberger
12K Followers 260 Following TPD-med chem-hiking-cocktails / while I have a connection to Arvinas, all opinions expressed are mine and do not represent the views or positions of the company
Ingo Hartung @HartungIngo
17K Followers 796 Following discovery chemistry nerd @Merckgroup; oncology, immunology, targeted protein degradation, ADCs; soccer, politics, tapas can slip into the feed; my own views
J. Am. Chem. Soc. @J_A_C_S
188K Followers 10K Following Research, news, and information from the Journal of the American Chemical Society.
Darryl B McConnell @D_B_McConnell
9K Followers 376 Following drug discoverer, medicinal chemist, wannaberunner, wannabeartist, builder of ponds and webmaster
Angewandte Chemie @angew_chem
114K Followers 3K Following Angewandte Chemie, a journal of the German Chemical Society (GDCh, @GDCh_aktuell) - a leading journal in #chemistry published by @WileyGlobal in @Weinheim
Chemjobber @Chemjobber
45K Followers 5K Following 1. A blog 2. Towards a quantitative understanding of the quality of the chemistry job market | #chemjobs: permanent industry/academia, #chempostdoc: postdocs
Guillaume Laconde @Glaconde34
5K Followers 99 Following Medicinal chemist, PROTAC and #TPD technology OXELTIS Scientist, https://t.co/F8c4eERuOA Communication Deputy for the SCT, https://t.co/8j34whJXIQ Tweets = my own.
Scott Bagley @BagPhos
8K Followers 1K Following Hexagon farmer #pfizerchemistry #TeamHeptanes @ACSorganic Program Chair. Posts/RTs my own. Life Goal: Never be the before slide on a process chem talk
Dan Nomura @DanNomura
19K Followers 9K Following Professor of Chemical Biology and Molecular Therapeutics at UC Berkeley; Departments of Chemistry and Molecular and Cell Biology; Co-Director of @MTI_UCB
Craig Crews @CraigMCrews
9K Followers 935 Following Yale Professor, Founder of @ArvinasInc, Halda Therapeutics, https://t.co/YoR6Yo3d3u, @[email protected]
Nick Chiappini 🏳�... @ndchiappini
13K Followers 3K Following Lover of weird rxns, reactive intermediates, and equitable sci. Asst Prof at UNCW. Queer AF. Ligand appreciator.
Total Synthesis @TotalSynthesis
18K Followers 1K Following @SoufianTibouti thinks Nature is the ultimate chemist.
超薬化学ちゃ @organischchemie
6K Followers 418 Following 製薬 / 創薬 / メドケム / 有機化学 / けもいんふぉマティクス フォロー リプはお気軽に 副作用ゼロのパリッと効くお薬-超薬を作りたい Medicinal Chemist, Organic Chemistry, Pharmaceuticals 論文情報の備忘録はこちら @TipsChem
Jay Bradner, M.D. @jaybradner
23K Followers 913 Following Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
Stuart Schreiber @SchreiberStuart
17K Followers 381 Following Truth-seeking scientist; equal parts Cajun, Mississippian, Irish, Hungarian.
Dennis X. Hu @DennisWhom
4K Followers 716 Following founder & CEO @drughuntersite after drug discovery in pharma/biotech (Genentech, RAPT Therapeutics) - discover faster in two min at https://t.co/lyNyXN7Pof
Bruce Booth @LifeSciVC
56K Followers 736 Following Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
Synthesis Workshop @MatthewHorwitz1
8K Followers 851 Following Synthesis Workshop is a video podcast exploring the frontiers of synthetic organic chemistry created by Matt Horwitz, Ph.D. https://t.co/iB4pKXqHuX
叢雲くすり (創�... @souyakuchan
10K Followers 3K Following 創薬なんもわからん #blockbustART (fan art tag) #blockbustART_AI (AI fan art tag)
Yehuda Katz @memalos_kats
390 Followers 2K Following CIO @ Family Office - Too young to be a GenXer, too old to be a Millennial. Pro-Meritocracy. Anti-Left. Toxic Masculinity. Italodisco. RT=Endorsements 🇬🇷🇮🇱
Navadheer @Navadheer_Y
2 Followers 56 Following PhD student at EPFL | Somewhere between chemistry, entrepreneurship & random ideas turning into real projects
Michael Vidne @mapkpathway
3 Followers 76 Following
Dr.Kireet Nallamothu @KireetRatan
414 Followers 2K Following Interventional Cardiologist @ Aster Ramesh Hospitals, Guntur. https://t.co/GQaUTAohaX
Hao(Robin) Dong @RobinDong_
134 Followers 296 Following Software developer on Linux. Worked on distributed storage, linux kernel. Now working on BigData, DeepLearning
Zaiqing Nie @ZaiqingNie
407 Followers 947 Following GDS Professor & Director of DAIR Lab @Tsinghua. Chief Scientist @PharMolix. Research: LLM, AI Agents & AI for Life Science
Magac @sdcgurgel_
0 Followers 9 Following
Yuta Aoki, D.Sc. @YutaMAoki
620 Followers 5K Following Doctor of Science in condensed-matter physics, Physicist, Materials Scientist, Data Scientist, Composer, Pianist. 🇯🇵🇹🇼
sunshine2020 @sunshin20_20
5 Followers 125 Following
yun wang @yunwang269242
0 Followers 47 Following
Chidera Christian @Zeribee13
2 Followers 205 Following
betterday @betterversion_b
472 Followers 671 Following Natural addict-book lover-รีวิวทุกอย่างที่ผ่านประสบการณ์จริง -หนังสือ -เดินทาง -เรื่องราว -E-book-Audio book-Kindle-GOT7-หยิ่นวอร์
amad iqbal chemist @ChemistAmad
0 Followers 88 Following
李倩倩 @Liqianqian1117
0 Followers 20 Following
aargade @MyMedChem
7 Followers 111 Following Health & Sciences: Compounding and periodic updates on US-FDA approved drugs, breakthroughs in drug discovery & development, & much more..
alex cen @herects
3 Followers 43 Following
しきちずょる @xiojbg5656
18 Followers 79 Following
Tim Gallagher @PlayballTim
153 Followers 1K Following Traveler, cyclist, entrepreneur, Wahoo, and baseball fan.
ToDaSё @anstweiner
2 Followers 166 Following
Mg @millergrams
0 Followers 0 Following
Willy Roque Barboza, ... @wroqueMD
1K Followers 2K Following PCCM physician-scientist | Drug Development | tweets are my own.
Michael Scherer @MAScherer
125 Followers 324 Following
Hemanth Singuluri @hemanthsin1
14 Followers 465 Following Pharmaceutical manufacturing and commercialization at Metaclipse Therapeutics. Obsessed with biotech, finance, crypto, and fitness.
Scott Beeler @Scott_Beeler
181 Followers 233 Following Heme-Onc Fellow @WashUHemOncFell | physician-scientist @KellyLBolton lab | myeloid neoplasms & clonal hematopoiesis | opinions my own
Sacha Mann @sachamann
388 Followers 1K Following Life science VC. Biotech CEO. Views are my own. @Creativedlab mentor. Co-founder @C100UK. Advisor at #dhf13 first #DigitalHealth forum in Europe. Cinephile.
Hitey Kataria @hitey_kataria
20 Followers 122 Following
api @plovesbanana
0 Followers 4K Following
Martin Dietrich, MD, ... @DoctorDietrich
1K Followers 886 Following
okilbahs @okilbahs
1 Followers 38 Following
Yi-Wei Teo @yiweiteo
107 Followers 3K Following
Terrevie @nmmm_sss
23 Followers 498 Following
Jake @givmethedata
1 Followers 59 Following I find drug targets (sometimes). Trying to learn more about the business side. Not financial advice.
IX @jirawatnine9
24 Followers 1K Following
Larry @lfholt
1K Followers 2K Following I got the AM. 🎄,🌆, ✝️,🏳️🌈, 🎶, 📈, 🏟, & 🌮. Roll Tide. (he/him). (AL-TX-OR-CA)
bk @k21hood
36 Followers 934 Following
CTTE @BigMo1959
28 Followers 4K Following
Joe @Drchik23
4K Followers 1K Following Biotech investor / gentleman / collector of useless information / Lost / I try to help others / Tweets are my opinions only--not investment advice.
Ciabatta Capital @CiabattaCapital
61 Followers 895 Following
Krithik Ramesh @KrithikTweets
949 Followers 828 Following AI + Math @MIT, compbio stuff @broadinstitute, prev: research @togethercompute
Keith Hornberger @KRHornberger
12K Followers 260 Following TPD-med chem-hiking-cocktails / while I have a connection to Arvinas, all opinions expressed are mine and do not represent the views or positions of the company
Ingo Hartung @HartungIngo
17K Followers 796 Following discovery chemistry nerd @Merckgroup; oncology, immunology, targeted protein degradation, ADCs; soccer, politics, tapas can slip into the feed; my own views
Darryl B McConnell @D_B_McConnell
9K Followers 376 Following drug discoverer, medicinal chemist, wannaberunner, wannabeartist, builder of ponds and webmaster
Scott Bagley @BagPhos
8K Followers 1K Following Hexagon farmer #pfizerchemistry #TeamHeptanes @ACSorganic Program Chair. Posts/RTs my own. Life Goal: Never be the before slide on a process chem talk
Dan Nomura @DanNomura
19K Followers 9K Following Professor of Chemical Biology and Molecular Therapeutics at UC Berkeley; Departments of Chemistry and Molecular and Cell Biology; Co-Director of @MTI_UCB
Dennis X. Hu @DennisWhom
4K Followers 716 Following founder & CEO @drughuntersite after drug discovery in pharma/biotech (Genentech, RAPT Therapeutics) - discover faster in two min at https://t.co/lyNyXN7Pof
Bruce Booth @LifeSciVC
56K Followers 736 Following Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
Bob the Grumpy Med Ch... @med_chemist
4K Followers 83 Following Jaded. Let me know when one of you figures out how the human body works.
Tatsuhiko Fujimoto @Tatsu_Fujimoto
5K Followers 805 Following 8100億円ブロックバスター博士・イノベーター・科学者・新薬探求・ 啓発 (ナルコレプシー・過眠症・てんかん・発達障害)・過眠症の自立支援/指定難病を要望; Innovator, Druggernaut, Advocacy, Pioneer & Lead for Orexin Research at Takeda
Tasuku Ishida @TasukuIshida1
900 Followers 86 Following うだつの上がらない某製薬会社の研究員からAI創薬の領域に転身しました。でもTPD領域は継続してウォッチしていきます。
島らっきょう大... @SimarakyoBanana
4K Followers 97 Following PhD/機能性食品研究→有機合成→ケミカルバイオロジー→助教→HTS→遺伝子治療→製薬会社で抗体医薬品をやっている変わり者/バイスペ抗体&次世代ADCなど/オンコロジー専門/発想力が勝負の研究者👨🔬がんや希少疾患、自己免疫疾患などの難病治療がライフワーク/技術ドリブン創薬/患者さんと研究者に最新情報を発信
Frontier Medicines @FrontierMeds
282 Followers 36 Following Frontier is a precision medicine company that has cutting-edge platform designed to generate medicines against previously undruggable disease-causing proteins.
Dennis @DennisCKoester
19 Followers 60 Following Drug Hunter / Reimagining Chemistry & Human Health / Husband / Dad
ONO PHARMA FOUNDATION @OnoInitiative
501 Followers 90 Following It was established to support academic research in relevant scientific fields, which is making significant impact on the therapeutic approaches for the patients
CAS @CASChemistry
8K Followers 666 Following Curating 150+ years of scientific knowledge to accelerate breakthroughs and improve lives. A division of @AmerChemSociety.
Amanda Yarnell @amandayarnell
2K Followers 933 Following Lead @HarvardChanCHC at @HarvardChanSPH | Board @drughuntersite | Formerly @cenmag. Opinions=mine. She/her. @amandayarnell on Post | @amandayarnell.bsky.social
Alex Goldberg @alexfgoldberg
6K Followers 4K Following AI-pilled; Portfolio Planning & Marketing at https://t.co/3UIpQmSlxi. bsky: https://t.co/QcpXsNAwvN / 🇨🇦🇺🇸
Practical_Fragments @PracticalFrag
1K Followers 13 Following A blog founded by Teddy Zartler and run by Dan Erlanson for Fragment-based Drug Discovery devotees to discuss non-confidential issues regarding fragments.
EFMC @EuroMedChem
5K Followers 705 Following The official twitter feed of the European Federation for Medicinal Chemistry and Chemical Biology.
c.kuttruff @CKuttruff
273 Followers 62 Following Medicinal Chemist | Scientist | Innovation Scout. Posts reflect my personal view only.
Daniel Gedder @danielgedder
144 Followers 278 Following PostDoc in Medicinal Chemistry at University College London - UCL
Stephan Hacker (inact... @StephanHacker2
5K Followers 2K Following Inactive account. Find me at: @stephanhacker2.bsky.social @[email protected] https://t.co/kPr9QkAN2S
Pengyu Yang @Pengyu19
828 Followers 677 Following Ph.D., Drug Hunter @RayThera | @PlexiumTx | @scrippsresearch alum | #discoverychemistry | #medchem #proteindegradation













